Celldex Therapeutics Management
Management criteria checks 3/4
Celldex Therapeutics' CEO is Anthony Marucci, appointed in May 2003, has a tenure of 21.33 years. total yearly compensation is $8.36M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.043% of the company’s shares, worth $1.18M. The average tenure of the management team and the board of directors is 8.2 years and 11.6 years respectively.
Key information
Anthony Marucci
Chief executive officer
US$8.4m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 21.3yrs |
| CEO ownership | 0.04% |
| Management average tenure | 8.2yrs |
| Board average tenure | 11.6yrs |
Recent management updates
Recent updates
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns
Jun 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jun 05We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jul 07An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued
Apr 21Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth
Feb 27We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate
Sep 07Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder
Jul 21Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Jul 14Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
May 25Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?
Feb 03Celldex: Pipeline Of Drug Candidates Is Worth A Look
Feb 01Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Sep 23We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth
Sep 15Celldex: Powerful Medicines To Yield Further Upsides
Jul 08Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
May 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$150m |
| Mar 31 2024 | n/a | n/a | -US$145m |
| Dec 31 2023 | US$8m | US$721k | -US$141m |
| Sep 30 2023 | n/a | n/a | -US$125m |
| Jun 30 2023 | n/a | n/a | -US$113m |
| Mar 31 2023 | n/a | n/a | -US$119m |
| Dec 31 2022 | US$5m | US$693k | -US$112m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$100m |
| Mar 31 2022 | n/a | n/a | -US$77m |
| Dec 31 2021 | US$6m | US$669k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$66m |
| Mar 31 2021 | n/a | n/a | -US$64m |
| Dec 31 2020 | US$3m | US$644k | -US$60m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$1m | US$619k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$50m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$50m |
| Dec 31 2018 | US$1m | US$608k | -US$151m |
| Sep 30 2018 | n/a | n/a | -US$146m |
| Jun 30 2018 | n/a | n/a | -US$165m |
| Mar 31 2018 | n/a | n/a | -US$177m |
| Dec 31 2017 | US$2m | US$598k | -US$93m |
Compensation vs Market: Anthony's total compensation ($USD8.36M) is about average for companies of similar size in the US market ($USD6.73M).
Compensation vs Earnings: Anthony's compensation has increased whilst the company is unprofitable.
CEO
Anthony Marucci (62 yo)
21.3yrs
Tenure
US$8,361,844
Compensation
Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.3yrs | US$8.36m | 0.043% $ 1.2m | |
| Founder | 21.3yrs | US$3.42m | 0.011% $ 303.4k | |
| Senior VP | 7.2yrs | US$2.95m | 0.042% $ 1.2m | |
| Senior Vice President of Regulatory Affairs | 6.9yrs | US$2.94m | 0.020% $ 551.9k | |
| Senior VP & Chief Medical Officer | 5.3yrs | US$2.97m | 0.026% $ 705.8k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Senior Vice President of Corporate Affairs & Administration | 7.3yrs | no data | 0.0028% $ 76.8k | |
| Senior VP & General Counsel | 3.7yrs | US$2.17m | 0.053% $ 1.5m | |
| Chief Business Officer & Senior VP | 13.2yrs | US$405.72k | no data | |
| Chief Product Development Officer & Senior VP | 10.2yrs | US$1.18m | 0.014% $ 374.2k | |
| Chief Commercial Officer & Senior VP | 9.2yrs | US$563.17k | 0.031% $ 859.2k |
8.2yrs
Average Tenure
62yo
Average Age
Experienced Management: CLDX's management team is seasoned and experienced (8.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 15.8yrs | US$8.36m | 0.043% $ 1.2m | |
| Co-Founder & Member of Scientific Advisory Board | 3.1yrs | no data | no data | |
| Independent Director | 27.7yrs | US$371.19k | 0.0042% $ 115.1k | |
| Independent Director | 16.5yrs | US$364.94k | 0.0039% $ 105.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.5yrs | US$377.44k | 0.019% $ 523.8k | |
| Independent Chair of the Board of Directors | 23.3yrs | US$385.77k | 0.0042% $ 114.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.3yrs | US$373.27k | 0.0010% $ 27.3k | |
| Independent Director | 2.3yrs | US$367.02k | 0% $ 0 |
11.6yrs
Average Tenure
72yo
Average Age
Experienced Board: CLDX's board of directors are seasoned and experienced ( 11.6 years average tenure).